|
Age, median years (range)
|
61 (21-79)
|
|
Primary site
|
|
Ovary
|
69 (93)
|
|
Peritoneal
|
2 (3)
|
|
Fallopian tube
|
3 (4)
|
|
Original stage
|
|
Ic
|
5 (7)
|
|
IIb
|
1 (1)
|
|
IIc
|
5 (7)
|
|
IIIa
|
4 (5)
|
|
IIIb
|
5 (7)
|
|
IIIc
|
45 (61)
|
|
IV
|
8 (11)
|
|
Unknown
|
1 (1)
|
|
Tumor grade
|
|
Well differentiate
|
11 (15)
|
|
Moderate well differentiate
|
21 (28)
|
|
Poorly differentiate/undifferentiate
|
36 (49)
|
|
Unknown
|
6 (8)
|
|
Histologic type
|
|
Serous
|
60 (81)
|
|
Mucinous
|
2 (3)
|
|
Clear cell
|
2 (3)
|
|
Endometroid
|
5 (7)
|
|
Undifferentiate
|
1 (1)
|
|
Other
|
4 (5)
|
|
Response to firs line therapy
|
|
Complete response (CR)
|
38 (51)
|
|
Partial response (PR)
|
8 (11)
|
|
Stable disease (SD)
|
2 (3)
|
|
Non-evaluated disease (NED)
|
26 (35)
|
|
Time from end of first line chemotherapy to relapse
|
|
Median months (range)
|
15.7 (6-80.9)
|
|
Relapse between 6 to 12 months
|
26 (35.1%)
|
|
Relapse >12 months
|
48 (64.9%)
|
